Klinische Studien Hepatologie

Hier finden Sie Informationen zu den aktuellen klinischen Studien in diesem Bereich.

Sie befinden sich hier:

Ansprechpartner

Aktuelle klinische Studien Hepatologie

A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis (PBC) with or without an lnadequate Response to Ursodeoxycholic Acid (UDCA)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared With Sorafenib In Patients With Untreated Locally Advanced Or Metastatic Hepatocellular Carcinoma
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH) (CLJN452A2202)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

A two-part randomized, double-blind, placebo-controlled multicenter <lose ranging and confirmatory study to assess the safety and efficacy of VA Y736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

Eine randomisierte, offene, multizentrische Phase Ill-Studie zum Vergleich der Wirkung und Sicherheit von BGB A317 gegenüber Sorafenib als First-Line-Behandlung bei Patienten mit nicht resezierbarem hepatozellulärem Karzinom
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

IMMULAB - A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

IMMUNIB - An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet acute HCV-V study (aHCV-V)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

Nicht-interventionelle Studie Deutsches Hepatitis C-Register (HCV Register)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

Prevention of Mortality with Long-­Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

SORAGO-HCC - Use of SORAfenib and/or ReGOrafenib in hepatocellular carcinoma (HCC) subsequent to another systemic first-line treatment. Eine prospektive nicht-interventionelle Studie (Beobachtungsstudie)
Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde

STELLARIS_Rollover 3
Ansprechpartner: Ansprechpartner: PD Dr. T. Müller, A.-C. Wilde